Business Wire·Sep 22, 2026, 9:02 AM ET

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Sydnexis, Inc. announced an agreement to sell its royalty rights for Ryjunea in Europe, the Middle East, & Africa to Ligand Pharmaceuticals Incorporated.
Ligand will provide a $23 million upfront payment to acquire 100% of the associated payments & related rights under Sydnexis' existing license with Santen.
Sydnexis retains all rights to SYD-101 in the U.S. & all other non-Santen licensed territories.
The capital infusion strengthens Sydnexis' balance sheet while advancing SYD-101 through the U.S. regulatory process.
Sydnexis aims to prepare for potential commercialization of SYD-101 in the U.S. in 2027 if approved.
SYD-101 is currently approved in the European Union & UK, where it is marketed as Ryjunea® under a license with Santen S.A.
Pediatric Progressive Myopia (PPM) is a degenerative eye disease affecting nearly one-third of children globally, with no current FDA-approved pharmaceutical options in the U.S. to slow progression.
Hogan Lovells Cadwalader US LLP served as legal counsel for Sydnexis in this transaction.